Mesna
 |
| Systematic (IUPAC) name |
| sodium 2-sulfanylethanesulfonate |
| Clinical data |
| AHFS/Drugs.com |
monograph |
| Pregnancy cat. |
B1 (Au), B (U.S.) |
| Legal status |
S4 (Au), POM (UK), ℞-only (U.S.) |
| Routes |
Oral, intravenous |
| Pharmacokinetic data |
| Bioavailability |
45–79% (Oral) |
| Metabolism |
Oxidised in circulation |
| Half-life |
0.36–8.3 hours |
| Excretion |
Renal |
| Identifiers |
| CAS number |
19767-45-4  N |
| ATC code |
R05CB05 V03AF01 |
| PubChem |
CID 29769 |
| ChemSpider |
27663  Y |
| UNII |
NR7O1405Q9 Y |
| KEGG |
D01459 Y |
| ChEMBL |
CHEMBL975 Y |
| Chemical data |
| Formula |
C2H5NaO3S2 |
| Mol. mass |
164.181 g/mol |
| SMILES |
eMolecules & PubChem |
-
InChI=1S/C2H6O3S2.Na/c3-7(4,5)2-1-6;/h6H,1-2H2,(H,3,4,5);/q;+1/p-1 Y
Key:XOGTZOOQQBDUSI-UHFFFAOYSA-M Y
|
 N(what is this?) (verify)
|
Mesna (INN) (
/ˈmɛznə/) is an organosulfur compound. It is used in cancer chemotherapy involving cyclophosphamide and ifosfamide as an adjuvant. It is marketed by Baxter as Uromitexan and Mesnex. MESNA is an acronym for 2-Mercaptoethane sulfonate Na (Na being the symbol for sodium).
[edit] As a chemotherapy adjuvant
Mesna is used therapeutically to reduce the incidence of haemorrhagic cystitis and haematuria when a patient receives ifosfamide or cyclophosphamide for cancer chemotherapy. These two anticancer agents, in vivo, may be converted to urotoxic metabolites such as acrolein.
Mesna assists to detoxify these metabolites by reaction of its sulfhydryl group with the vinyl group. It also increases urinary excretion of cysteine.
Outside North America, mesna is also used as a mucolytic agent, working in the same way as acetylcysteine; it is sold for this indication as Mistabron[1] and Mistabronco.
[edit] Administration
It is administered intravenously, but oral dosing has been investigated.[2]
[edit] Mechanism
It is believed to act as an antioxidant.[3]
[edit] References
[edit] External links
(what is this?) (verify)
/ˈmɛznə/) is an organosulfur compound. It is used in cancer chemotherapy involving cyclophosphamide and ifosfamide as an adjuvant. It is marketed by Baxter as Uromitexan and Mesnex. MESNA is an acronym for 2-Mercaptoethane sulfonate Na (Na being the symbol for sodium).
